Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States.

Zhao Y, Johnston SS, Smith DM, McMorrow D, Krege J, Krohn K.

Bone. 2014 Mar;60:221-6. doi: 10.1016/j.bone.2013.12.016. Epub 2013 Dec 18.

PMID:
24361596
2.

Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.

Zhao Y, Johnston SS, Smith DM, McMorrow D, Krohn K, Krege J.

Osteoporos Int. 2013 Sep;24(9):2525-33. doi: 10.1007/s00198-013-2324-7. Epub 2013 Mar 26.

PMID:
23529293
3.

Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.

Hazel-Fernandez L, Louder AM, Foster SA, Uribe CL, Burge RT.

BMC Musculoskelet Disord. 2013 Jan 3;14:4. doi: 10.1186/1471-2474-14-4.

4.

The impact of teriparatide adherence and persistence on fracture outcomes.

Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES.

Osteoporos Int. 2012 Mar;23(3):1103-13. doi: 10.1007/s00198-011-1843-3. Epub 2011 Dec 8.

PMID:
22159748
5.

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.

Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD.

BMC Gastroenterol. 2012 Sep 24;12:132. doi: 10.1186/1471-230X-12-132.

6.

Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.

Modi A, Siris ES, Tang J, Sen S.

Curr Med Res Opin. 2015 Apr;31(4):757-65. doi: 10.1185/03007995.2015.1016605. Epub 2015 Feb 23.

PMID:
25661017
7.
8.

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.

Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.

J Med Econ. 2012;15(6):1039-50. doi: 10.3111/13696998.2012.688903. Epub 2012 May 24.

PMID:
22533526
9.

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L.

BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.

10.

Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.

Boytsov N, Zhang X, Sugihara T, Taylor K, Swindle R.

Curr Med Res Opin. 2015;31(9):1665-75. doi: 10.1185/03007995.2015.1066765. Epub 2015 Jul 23.

PMID:
26121328
11.

Retrospective database study to assess the economic impact of hip fracture in the United Kingdom.

Lambrelli D, Burge R, Raluy-Callado M, Chen SY, Wu N, Schoenfeld MJ.

J Med Econ. 2014 Nov;17(11):817-25. doi: 10.3111/13696998.2014.959588. Epub 2014 Sep 12.

PMID:
25164473
12.

Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.

Chastek B, Kulakodlu M, Valluri S, Seal B.

Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.

PMID:
23816773
13.

Impact of medication adherence on hospitalization risk and healthcare cost.

Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS.

Med Care. 2005 Jun;43(6):521-30.

PMID:
15908846
14.

Clinical and economic characteristics of hip fracture patients with and without muscle atrophy/weakness in the United States.

Zhao Y, Chen SY, Lee YC, Wu N.

Arch Osteoporos. 2013;8:127. doi: 10.1007/s11657-013-0127-2. Epub 2013 Mar 27.

PMID:
23532737
15.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9. Epub 2007 Sep 25.

PMID:
17895328
16.

Characteristics of hip fracture patients with and without muscle atrophy/weakness: predictors of negative economic outcomes.

Cui Z, Schoenfeld MJ, Bush EN, Chen Y, Burge R.

J Med Econ. 2015 Jan;18(1):1-11. doi: 10.3111/13696998.2014.969433. Epub 2014 Oct 8.

PMID:
25271379
17.

Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.

Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM.

Hepatology. 2012 Nov;56(5):1651-60. doi: 10.1002/hep.25842. Epub 2012 Oct 9. Erratum in: Hepatology. 2013 Sep;58(3):1193.

PMID:
22610658
18.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

Curr Med Res Opin. 2010 Dec;26(12):2861-9. doi: 10.1185/03007995.2010.533648. Epub 2010 Nov 9.

PMID:
21062136
19.

Cost and utilization outcomes of opioid-dependence treatments.

Baser O, Chalk M, Fiellin DA, Gastfriend DR.

Am J Manag Care. 2011 Jun;17 Suppl 8:S235-48.

PMID:
21761950
20.

Resource utilization and costs before and after total joint arthroplasty.

Bozic KJ, Stacey B, Berger A, Sadosky A, Oster G.

BMC Health Serv Res. 2012 Mar 23;12:73. doi: 10.1186/1472-6963-12-73.

Items per page

Supplemental Content

Write to the Help Desk